These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 36998143)

  • 1. The Clinical Safety and Efficacy of Targeted PD-L1 Therapy with Durvalumab in Solid Tumors.
    Chen M; Jiang J; Chen J; Wang M; Lu Y; Liu L; Zhao L; Wang L
    Curr Drug Targets; 2023; 24(7):584-598. PubMed ID: 36998143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
    Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA;
    Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer.
    Massard C; Gordon MS; Sharma S; Rafii S; Wainberg ZA; Luke J; Curiel TJ; Colon-Otero G; Hamid O; Sanborn RE; O'Donnell PH; Drakaki A; Tan W; Kurland JF; Rebelatto MC; Jin X; Blake-Haskins JA; Gupta A; Segal NH
    J Clin Oncol; 2016 Sep; 34(26):3119-25. PubMed ID: 27269937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma.
    Faiena I; Cummings AL; Crosetti AM; Pantuck AJ; Chamie K; Drakaki A
    Drug Des Devel Ther; 2018; 12():209-215. PubMed ID: 29416316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and Efficacy of Programmed Cell Death 1 and Programmed Death Ligand-1 Inhibitors in the Treatment of Cancer: An Overview of Systematic Reviews.
    Ou SL; Luo J; Wei H; Qin XL; Du SY; Wang S; Jiang Q
    Front Immunol; 2022; 13():953761. PubMed ID: 35911744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analytical Validation and Clinical Utility of an Immunohistochemical Programmed Death Ligand-1 Diagnostic Assay and Combined Tumor and Immune Cell Scoring Algorithm for Durvalumab in Urothelial Carcinoma.
    Zajac M; Boothman AM; Ben Y; Gupta A; Jin X; Mistry A; Sabalos C; Nielsen A; Manriquez G; Barker C; Antal J; Wang P; Patil P; Schechter N; Rebelatto MC; Walker J
    Arch Pathol Lab Med; 2019 Jun; 143(6):722-731. PubMed ID: 30457897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Durvalumab for the treatment of urothelial carcinoma.
    Alsharedi M; Srivastava R; Elmsherghi N
    Drugs Today (Barc); 2017 Dec; 53(12):647-652. PubMed ID: 29517083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.
    Zhou TC; Sankin AI; Porcelli SA; Perlin DS; Schoenberg MP; Zang X
    Urol Oncol; 2017 Jan; 35(1):14-20. PubMed ID: 27816403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.
    Zandberg DP; Algazi AP; Jimeno A; Good JS; Fayette J; Bouganim N; Ready NE; Clement PM; Even C; Jang RW; Wong S; Keilholz U; Gilbert J; Fenton M; Braña I; Henry S; Remenar E; Papai Z; Siu LL; Jarkowski A; Armstrong JM; Asubonteng K; Fan J; Melillo G; Mesía R
    Eur J Cancer; 2019 Jan; 107():142-152. PubMed ID: 30576970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Programmed Cell Death-Ligand-1 expression in Bladder Schistosomal Squamous Cell Carcinoma -
    Madureira AC
    Front Immunol; 2022; 13():955000. PubMed ID: 36148227
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study.
    Powles T; O'Donnell PH; Massard C; Arkenau HT; Friedlander TW; Hoimes CJ; Lee JL; Ong M; Sridhar SS; Vogelzang NJ; Fishman MN; Zhang J; Srinivas S; Parikh J; Antal J; Jin X; Gupta AK; Ben Y; Hahn NM
    JAMA Oncol; 2017 Sep; 3(9):e172411. PubMed ID: 28817753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1 PET/CT Imaging with Radiolabeled Durvalumab in Patients with Advanced-Stage Non-Small Cell Lung Cancer.
    Smit J; Borm FJ; Niemeijer AN; Huisman MC; Hoekstra OS; Boellaard R; Oprea-Lager DE; Vugts DJ; van Dongen GAMS; de Wit-van der Veen BJ; Thunnissen E; Smit EF; de Langen AJ
    J Nucl Med; 2022 May; 63(5):686-693. PubMed ID: 34385342
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Verhoeff SR; van de Donk PP; Aarntzen EHJG; Oosting SF; Brouwers AH; Miedema IHC; Voortman J; Menke-van der Houven van Oordt WC; Boellaard R; Vriens D; Slingerland M; Hermsen R; Grunsven IVE; Heskamp S; van Herpen CML
    J Nucl Med; 2022 Oct; 63(10):1523-1530. PubMed ID: 35512998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial.
    Siu LL; Even C; Mesía R; Remenar E; Daste A; Delord JP; Krauss J; Saba NF; Nabell L; Ready NE; Braña I; Kotecki N; Zandberg DP; Gilbert J; Mehanna H; Bonomi M; Jarkowski A; Melillo G; Armstrong JM; Wildsmith S; Fayette J
    JAMA Oncol; 2019 Feb; 5(2):195-203. PubMed ID: 30383184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Programmed Death 1 and Programmed Death Ligand 1 Inhibitors in Advanced and Recurrent Urothelial Carcinoma: Meta-analysis of Single-Agent Studies.
    Tafuri A; Smith DD; Cacciamani GE; Cole S; Shakir A; Sadeghi S; Vogelzang NJ; Quinn D; Gill PS; Gill IS
    Clin Genitourin Cancer; 2020 Oct; 18(5):351-360.e3. PubMed ID: 32146152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concurrent irradiation with the anti-programmed cell death ligand-1 immune checkpoint blocker durvalumab: Single centre subset analysis from a phase 1/2 trial.
    Levy A; Massard C; Soria JC; Deutsch E
    Eur J Cancer; 2016 Nov; 68():156-162. PubMed ID: 27764686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays.
    Schwamborn K; Ammann JU; Knüchel R; Hartmann A; Baretton G; Lasitschka F; Schirmacher P; Braunschweig T; Tauber R; Erlmeier F; Hieke-Schulz S; Weichert W
    Virchows Arch; 2019 Nov; 475(5):599-608. PubMed ID: 31267201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inter- and intraobserver agreement of programmed death ligand 1 scoring in head and neck squamous cell carcinoma, urothelial carcinoma and breast carcinoma.
    Downes MR; Slodkowska E; Katabi N; Jungbluth AA; Xu B
    Histopathology; 2020 Jan; 76(2):191-200. PubMed ID: 31243779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
    Rebelatto MC; Midha A; Mistry A; Sabalos C; Schechter N; Li X; Jin X; Steele KE; Robbins PB; Blake-Haskins JA; Walker J
    Diagn Pathol; 2016 Oct; 11(1):95. PubMed ID: 27717372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.